Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 43

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 43
---
contract research organizations. Management evaluates its estimates and assumptions on an ongoing basis using historical experience
and other factors, including the current economic environment, and adjusts when facts and circumstances dictate. These estimates are
based on information available as of the date of the unaudited condensed consolidated financial statements; therefore, actual
results could differ from those estimates.

Loss
per share

Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants, which
are included under the treasury stock method when dilutive.

    F-6

The
following number of stock options, pre-funded warrants and warrants were excluded from the calculation of diluted loss per share because
their effect would have been anti-dilutive for the periods presented (share data):

SCHEDULE OF ANTI-DILUTIVE SECURITIES  

    Weighted average 

    Three months ended  
    Nine months ended 

    September 30  
    September 30 

    2025  
    2024  
    2025  
    2024 
  
    Outstanding stock options 
     104,568  
     88,852  
     103,297  
     69,827 
  
    Pre-funded warrants 
     136,282  
     -  
     45,594  
     - 
  
    Warrants 
     1,360,786  
     144,578  
     659,481  
     110,385 

Research
and development expenses

Research
and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research
and development activities, including clinical trials and professional services. All costs associated with research and development are
expensed as incurred.

The
Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract
manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods
over which services or materials are provided to the Company. Accruals are recorded